Cited by 22Maternal and fetal healthcareReproductive Health and ContraceptionMaternal and Perinatal Health Interventions

Effectiveness and safety of misoprostol distributed to antenatal women to prevent postpartum haemorrhage after child-births: a stepped-wedge cluster-randomized trial

Open access
Ononge, Sam, Campbell, Oona M. R., Kaharuza, Frank, Lewis, James J., Fielding, Katherine, Mirembe, Florence·2015·BMC Pregnancy and Childbirth

Abstract

BACKGROUND: Oral misoprostol, administered by trained health-workers is effective and safe for preventing postpartum haemorrhage (PPH). There is interest in expanding administration of misoprostol by non-health workers, including task-shifting to pregnant women themselves. However, the use of misoprostol for preventing PPH in home-births remains controversial, due to the limited evidence to support self-administration or leaving it in the hands of non-health workers. This study aimed to determine if antenatally distributing misoprostol to pregnant women to self-administer at home birth reduces PPH. METHODS: Between February 2013 and March 2014, we conducted a stepped-wedge cluster-randomized trial in six health facilities in Central Uganda. Women at 28+ weeks of gestation attending antenatal care were eligible. Women in the control-arm received the standard-of-care; while the intervention-arm were offered 600 mcg of misoprostol to swallow immediately after birth of baby, when oxytocin was not available. The primary outcome (PPH) was a drop in postpartum maternal haemoglobin (Hb) by ≥ 2 g/dl, lower than the prenatal Hb. Analysis was by intention-to-treat at the cluster level and we used a paired t-tests to assess whether the mean difference between the control and intervention groups was statistically significant. RESULTS: 97% (2466/2545) of eligible women consented to participate; 1430 and 1036 in the control and intervention arms respectively. Two thousand fifty-seven of the participants were successfully followed up and 271 (13.2%) delivered outside a health facility. There was no significant difference between the study group in number of women who received a uterotonic at birth (control 80.4% vs intervention 91.4%, mean difference = -11.0%, 95% confidence interval [CI] -25.7% to 3.6%, p = 0.11). No woman took misoprostol before their baby's birth. Shivering and fever were 14.9% in the control arm compared to 22.2% in the intervention arm (mean difference = -7.2%, 95% CI -11.1% to -3.7%), p = 0.005). There was a slight, but non-significant, reduction in the percentage of women with Hb drop ≥ 2g/dl from 18.5% in the control arm to 11.4% in the intervention arm (mean difference = 7.1%, 95% CI -3.1% to 17.3%, p = 0.14). Similarly, there was no significant difference between the groups in the primary outcome in the women who delivered at home (control 9.6% vs intervention 14.5%, mean difference -4.9; 95% CI -12.7 to 2.9), p = 0.17). CONCLUSION: This study was unable to detect a significant reduction in PPH following the antenatal distribution of misoprostol. The study was registered with Pan-African Clinical Trials Network ( PACTR201303000459148, on 19/11/2012).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12884-015-0750-6

Cites

38 of 39 references verified1 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The stepped-wedge design in Ononge et al. 2015 was chosen because current evidence on misoprostol use and postpartum hemorrhage would render a placebo-controlled trial unethical, and all facilities ultimately get the intervention.

    “The stepped-wedge design was chosen because current evidence on misoprostol use and postpartum hemorrhage would render a placebo-controlled trial unethical, and all facilities ultimately get the intervention.”
  • The sample size in Ononge et al. 2015 was calculated considering a between-cluster correlation coefficient km = 0.2, a minimum of 200 pregnant women per health facility in each phase, and a proportion experiencing postpartum hemorrhage of 12.0%.

    “The sample size was calculated considering a between-cluster correlation coefficient km = 0.2, a minimum of 200 pregnant women per health facility in each phase, and a proportion experiencing postpartum hemorrhage of 12.0%.”
  • The random sequence for starting the intervention in Ononge et al. 2015 was determined using a computer-generated number sequence. The principal investigator implemented the randomization.

    “The random sequence for starting the intervention was determined using a computer-generated number sequence. The principal investigator implemented the randomization”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Ononge, S., Campbell, O. M. R., Kaharuza, F., Lewis, J. J., Fielding, K., & Mirembe, F.
Affiliations
  • Makerere University (UG)
  • London School of Hygiene & Tropical Medicine (GB)
Corresponding author
Ononge, Sam
Venue
BMC Pregnancy and Childbirth
Published
2015-11-26
Volume
15
Issue
1
Pages
315-315
ISSN
1471-2393 (ISSN-L)
OpenAlex
W2189446016
Cited by
22
References
39
Citations by year
2026: 1 · 2025: 2 · 2023: 2 · 2021: 1 · 2020: 6 · 2019: 2 · 2018: 4 · 2017: 2 · 2016: 1 · 2012: 1
FWCI
2.33
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • BMC Pregnancy and Childbirth (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion)
  • LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
Funders
Wellcome Trust (087540)
Topics
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Maternal and fetal healthcare
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Health and Contraception
  • Health Sciences › Medicine › Obstetrics and Gynecology › Maternal and Perinatal Health Interventions
Keywords
misoprostol, postpartum hemorrhage, home birth, oxytocin, uterotonic agents, maternal hemoglobin, adverse effects, task shifting, prenatal care, Uganda, resource-limited settings, obstetric care, health workforce shortage
MeSH terms
Administration, Oral, Adult, Drug Administration Schedule, Female, Fever, Hemoglobins, Postpartum Hemorrhage, Home Childbirth, Humans, Oxytocics, Pregnancy, Self Administration, Shivering, Uganda, Cluster Analysis, Misoprostol, Delivery, Obstetric, Postpartum Period, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review